Ninety One UK Ltd Invests $1.63 Million in Becton, Dickinson and Company $BDX

Key Points

• Ninety One UK Ltd invested approximately $1.63 million in Becton, Dickinson and Company, acquiring 9,458 shares of the medical instruments supplier.
• Institutional investors own 86.97% of BDX's stock, with several firms significantly increasing their stakes recently, including Brighton Jones LLC and Wealth Enhancement Advisory Services LLC.
• Becton, Dickinson and Company reported a 10.4% year-over-year revenue growth and exceeded earnings estimates, announcing a quarterly dividend of $1.04, reflecting a yield of 2.2%.

Ninety One UK Ltd acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 9,458 shares of the medical instruments supplier's stock, valued at approximately $1,629,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BDX. Brighton Jones LLC boosted its position in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after acquiring an additional 877 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Becton, Dickinson and Company by 50.6% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock valued at $18,808,000 after purchasing an additional 27,581 shares during the last quarter. FORA Capital LLC purchased a new position in Becton, Dickinson and Company during the first quarter worth about $3,458,000. Foster Victor Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company in the 1st quarter worth about $6,406,000. Finally, GAMMA Investing LLC grew its holdings in Becton, Dickinson and Company by 29.9% in the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock valued at $744,000 after buying an additional 748 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director owned 22,226 shares of the company's stock, valued at $4,167,375. The trade was a 3.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,023 shares of company stock valued at $562,036. Company insiders own 0.36% of the company's stock.

Analyst Ratings Changes

BDX has been the topic of several research analyst reports. Morgan Stanley raised their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Royal Bank Of Canada assumed coverage on shares of Becton, Dickinson and Company in a report on Thursday, September 25th. They issued a "sector perform" rating and a $211.00 price target on the stock. Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research note on Friday, August 8th. Wall Street Zen raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Argus lifted their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Three investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company has a consensus rating of "Hold" and a consensus price target of $205.40.

Becton, Dickinson and Company Trading Up 2.0%

NYSE:BDX opened at $190.90 on Thursday. The business's 50-day moving average is $188.71 and its two-hundred day moving average is $188.20. The firm has a market capitalization of $54.72 billion, a PE ratio of 34.33, a price-to-earnings-growth ratio of 1.51 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company's revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were paid a $1.04 dividend. The ex-dividend date was Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.